How the type of risk reduction influences required sample sizes in randomised clinical trials

被引：3

作者：

Bruynesteyn, K ^{[1
]}

Wanders, A ^{[1
]}

Landewé, R ^{[1
]}

van der Heijde, D ^{[1
]}

机构：

[1] Univ Hosp Maastricht, Div Rheumatol, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷 / 11期

关键词：

D O I：

10.1136/ard.2003.014035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To increase change between groups, randomised clinical trials (RCT) often include patients with high risk for a particular outcome, by inclusion criteria that select predictors for that outcome. This increases the statistical power, and fewer patients are required for that RCT. The way in which patient selection influences the power, and thus sample size required, depends on how an intervention reduces the individual risk: by an absolute or relative risk reduction model.

引用

页码：1368 / 1371

页数：4

共 14 条

[1] Statistics Notes - Interaction revisited: the difference between two estimates
Altman, DG
Bland, JM
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7382): : 219 - 219
[2] Boers M, 2001, ARTHRITIS RHEUM, V44, P2242, DOI 10.1002/1529-0131(200110)44:10<2242::AID-ART386>3.0.CO
[3] 2-F
[4] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Boers, M
Verhoeven, AC
Markusse, HM
vandeLaar, MAFJ
Westhovens, R
vanDenderen, JC
vanZeben, D
Dijkmans, BAC
Peeters, AJ
Jacobs, P
vandenBrink, HR
Schouten, HJA
vanderHeijde, DMFM
Boonen, A
vanderLinden, S
[J]. LANCET, 1997, 350 (9074) : 309 - 318
[5] Combe B, 2001, ARTHRITIS RHEUM, V44, P1736, DOI 10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO
[6] 2-I
[7] Long-term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup
Drossaers-Bakker, KW
Zwinderman, AH
Vlieland, TPMV
Van Zeben, D
Vos, K
Breedveld, FC
Hazes, JMW
[J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (04): : 383 - 390
[8] Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis:: a double blind randomised placebo controlled trial
Gerards, AH
Landewé, RBM
Prins, APA
Bruijn, GAW
Thè, HSG
Laan, RFJM
Dijkmans, BAC
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) : 291 - 296
[9] Matthews JNS, 1996, BRIT MED J, V313, P862
[10] Commentary: Relative treatment effects are consistent across the spectrum of underlying risks ... usually
McAlister, FA
[J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) : 76 - 77

← 1 2 →